Case Type: Mergers & Acquisitions

Oxford Immunotec Global PLC (OXFD) relating to its proposed sale to PerkinElmer, Inc. Under the terms of the agreement, OXFD shareholders will receive $22.00 in cash per share they own.

Deerfield Healthcare Technology Acquisitions Corp. (DFHT) relating to its proposed merger with CareMax Medical Group,LLC and IMC Medical Group Holdings, LLC. Under the terms of the agreement, the companies will merge into a new publicly traded entity, CareMax, Inc.

Coherent, Inc. (COHR) relating to its proposed acquisition by II-VI, Inc. Under the terms of the agreement, COHR shareholders will receive $220.00 in cash and 0.91 shares of II-VI per share they own.

Crescent Acquisition Corp. (“CRSA” or the “Company”) (CRSA) relating to its proposed acquisition of LiveVox. Under the terms of the agreement, CRSA will acquire LiveVox through a reverse merger, with LiveVox emerging as a publicly traded company.

FBL Financial Group, Inc. (FFG) relating to its proposed acquisition by Farm Bureau Property & Casualty Insurance Company. Under the terms of the agreement, FFG shareholders will receive $56.00 in cash per share.

QUALCOMM Inc. (QCOM) relating to its proposed acquisition of NuVia, Inc.. Under the terms of the agreement, QCOM will merge with and into NuVia, with NuVia surviving the merger as a wholly owned subsidiary of QCOM.

National Holdings Corporation (NHLD) relating to its proposed acquisition by B. Riley Financial, Inc. Under the terms of the tender offer, NHLD shareholders will receive $3.25 in cash per share they own.

Cantel Medical Corp. (CMD) relating to its proposed acquisition by STERIS plc. Under the terms of the agreement, CMD shareholders will receive $16.93 in cash and 0.33787 shares of STERIS stock per share they own.

SMTC Corporation (SMTX) relating to its proposed acquisition by an affiliate of H.I.G. Capital. Under the terms of the agreement, SMTX shareholders will receive $6.044 in cash per share they own.

Anchiano Therapeutics Ltd. (ANCN) relating to its proposed merger with Chemomab Ltd. Under the terms of the agreement, and before additional PIPE financing, ANCN shareholders are expected to own only 10% of the combined company.